论文部分内容阅读
目的 :探讨高危角膜移植病例在行大直径角膜移植手术后的安全性和有效性。方法 :对高危角膜移植病例 19例 (19眼 )采用 >9mm的大直径角膜植片的角膜穿透性移植术治疗角膜病 19例 (19眼 ) ,并与非高危角膜移植组 2 5例 (2 5眼 )进行对照。结果 :两组比较 ,裸眼视力≥ 0 .5者大植片组有 11眼 (占 5 7.9% ) ,小植片组有 10眼 (占 40 .0 % )可以看出大植片组视力恢复优于小植片组角膜移植病例 (P<0 .0 5 )。在手术后 12个月时大植片组较小植片组角膜散光的发生比较低 (P<0 .0 5 )。本文观察结果大角膜植片排斥反应的治疗并不因植片大而更困难。结论 :治疗角膜病变范围较大的高危角膜病患者 ,采用 >9mm直径的角膜植片行角膜移植的手术方法是安全可行的
Objective: To investigate the safety and efficacy of high-risk corneal transplantation in large diameter corneal transplantation. Methods: Nineteen patients (19 eyes) with high-risk corneal transplantation were treated with corneal penetrating grafting (> 9 mm) 25 eyes) for comparison. Results: There was 11 eyes (5 7.9%) in the bare-stained eyes ≥0.5 and 10 eyes in the small-stitched eyes (40.0%). The visual acuity recovery Small graft group corneal transplantation cases (P <0. 05). The incidence of corneal astigmatism was lower in the graft-versus-graft group at 12 months after surgery (P <0.05). This observation results in the treatment of large corneal graft rejection is not due to larger and more difficult grafts. CONCLUSION: Corneal grafting with> 9 mm diameter corneal grafts is safe and feasible for the treatment of high-risk keratopathy patients with a wide range of corneal lesions